Clearmind Medicine Initiates 12-Month Preclinical Study of MEAI Plus Tirzepatide for 15–20% Weight Reduction
CMND•Clearmind Medicine signed a 12-month preclinical agreement to evaluate its MEAI candidate with tirzepatide for improved metabolic outcomes and reduced weight regain. Previous mouse studies showed MEAI cut bodyweight by about 15-20% through higher energy expenditure, offering a differentiated complement to GLP-1 therapies.
1. Research Agreement and Study Design
Clearmind Medicine entered a 12-month preclinical research agreement with Yissum Research Development Company to test concurrent and maintenance use of its MEAI candidate alongside tirzepatide in diet-induced obese mice. The study, led by Prof. Joseph Tam at the Hebrew University Obesity and Metabolism Lab, will assess weight regain, metabolic markers, and energy expenditure.
2. MEAI Preclinical Efficacy Data
Prior preclinical experiments showed that MEAI achieved approximately 15-20% body-weight reduction in obese mice by increasing energy expenditure and fat utilization without sacrificing lean mass. The current trial will evaluate whether MEAI can sustain post-treatment benefits and enhance metabolic outcomes when combined with or following tirzepatide administration.
3. Strategic Implications for Clearmind
This program broadens Clearmind’s focus from neuroplastogen compounds into the obesity and metabolic disease space, potentially addressing unmet needs in long-term weight maintenance after GLP-1 therapy. Successful results could position MEAI as a differentiated maintenance or adjunct treatment, opening new commercial and partnership opportunities in the fast-growing obesity market.
